CiRT Inaugural meeting 2025

LIST OF ABSTRACTS

DIVERSITY IN HUMAN INKT CELLS ACROSS IMMUNOLOGICALLY RELEVANT HEMATOLOGIC TISSUES

Melissa Mavers[1], Reyka G. Jayasinghe[2], Derek Hollingsworth [3], Nathan C. Schedler [1], Emily Landy[1], Chaiyaporn Boonchalermvichian[4], Biki Gupta[4], Hao Yan[4], Jeanette Baker[4], Kenneth I. Weinberg[3], Robert S. Negrin[4]

[1] Department of Pediatrics, Washington University in St. Louis School of Medicine, St. Louis, USA

[2] Department of Medicine, Washington University in St. Louis School of Medicine, St. Louis, USA

[3] Department of Pediatrics, Stanford University School of Medicine, Palo Alto, USA

[4] Department of Medicine, Stanford University School of Medicine, Palo Alto, USA

ALPHA-GALACTOSYL CERAMIDE AS ADJUVANT IN VACCINES FOR CANCER AND INFECTIOUS DISEASE

Mads Clausen

Department of Chemistry, Technical University of Denmark, Kongens Lyngby, Denmark

MODULATING LIPID METABOLISM TO ENHANCE ANTITUMOR NKT CELL RESPONSES

Tonya Webb

Microbiology and Immunology, University of Maryland, Baltimore, Baltimore, USA

IPSC-DERIVED HER2 CAR-INKT CELLS BOOST ANTI-TUMOR ACTIVITY OF CTLS IN A TUMOR XENOGRAFT MOUSE MODEL

Lilin Zhang[1], Koichiro Shioya[1], Tomio Matsumura[1], Akane Urakami[1], Tomokuni Shigeura[1], Aki Naito[2], Yuji Mishima[2], Yu-Ching Lin[1], Mio Shiraishi[1], Haruhiko Koseki[3], Shinichiro Motohashi[4]

[1] Pharmaceutical Development, BrightPath Biotherapeutics Co., Ltd., Tokyo, Japan

[2] Research & Early Development, BrightPath Biotherapeutics Co., Ltd., Tokyo, Japan

[3] Center for Integrative Medical Sciences, Riken, Yokohama, Japan

[4] Department of Medical Immunology, Graduate School of Medicine, Chiba University, Chiba, Japan

HUMAN INKT CELLS INDUCE ACTIVATION AND SUBSET-DEPENDENT CELL DEATH OF MACROPHAGES

Fátima Macedo[1], Mariana Cruz[2], Jose Pedro Loureiro[2], Maria Jose Oliveira[2]

[1] Faculty of Medicine and Biomedical Sciences, University of Algarve, Faro, Portugal

[2] Institute for Research and Innovation in Health (i3S), University of Porto, Porto, Portugal

DEVELOPMENT OF CAR-INKT CELLS FOR THE TREATMENT AND HAEMATOLOGICAL MALIGNANCIES AND SOLID TUMOURS

Arovella Therapeutics Limited

INKT CELLS DEVELOP THROUGH A 4-STAGE PATHWAY IN HUMAN

Naeimeh Tavakolinia[1], Daniel Pellicci[1]

[1] Microbiology and Immunology, University of Melbourne, Melbourne, Australia

ANALYSIS OF INKT-DC ADJUVANCY MECHANISMS THROUGH RNASEQ

Sarah Ferguson[1], Mariah Riel [2], Dana Baiu[1], Nikhila Bharadwaj[1], Eric Johannsen[2], Jenny Gumperz[1]

[1] Medical Microbioloy and Immunology, University of Wisconsin School of Medicine and Public Health, Madison, United States of America

[2] Oncology, University of Wisconsin School of Medicine and Public Health, Madison, United States of America

HISTONE DEACETYLASE 3 CONTROLS MULTIPLE KEY ASPECTS OF INKT CELL DEVELOPMENT

Li Zhou[1,2,4,5], Jie Wang[1,2], Quanhui Zheng[1,2], Kalpana Subedi[1,2], Tingting Liu[1,2], Bobby Zuniga[1,2], James Ge[1,2], Ian Loveless[1,3], Guihua Li[1,2], Indra Adrianto[1,2,3,5], Aimin Jiang[1,2,5], Qing-Sheng Mi[1,2,4,5]

[1] Center for Cutaneous Biology and Immunology Research, Department of Dermatology, Henry Ford Health, Detroit, Michigan, USA.

[2] Immunology Research Program, Henry Ford Cancer Institute, Henry Ford Health, Detroit, Michigan, USA.

[3] Center for Bioinformatics, Department of Public Health Sciences, Henry Ford Health, Detroit, Michigan, USA

[4] Department of Internal Medicine, Henry Ford Health, Detroit, Michigan, USA.

[5] Department of Medicine, College of Human Medicine, Michigan State University, East Lansing, Michigan, USA

CD8+ INKT CELLS ARE PRESENT IN OLD MICE (8 TO 12 MONTHS) UNDER B6/129 BACKGROUND

Inês Mondragão-Rodrigues[1], Leonardo Matias[2], Catarina Meireles[3], Fátima Macedo[4]

[1] Cell Activation and Gene Expression Group; Doctoral Program of Biomedical Sciences, Instituto de Investigação e Inovação em Saúde (i3S); Instituto de Ciências Biomédicas Abel Salazar, Porto, Portugal

[2] Chemistry Department; Cell Activation and Gene Expression Group, University of Aveiro; Instituto de Investigação e Inovação em Saúde (i3S), Porto, Portugal

[3] Translational Cytometry Facility, Instituto de Biologia Molecular e Celular (IBMC); Instituto de Investigação e Inovação em Saúde (i3S), Porto, Portugal

[4] Faculty Medicine and Biomedical Sciences; Cell Activation and Gene Expression Group, University of Algarve; Instituto de Investigação e Inovação em Saúde (i3S), Porto, Portugal

DIFFERENTIAL GENE EXPRESSION ANALYSIS OF INKTS CULTURED FOR 4 AND 6 WEEKS

Robin Klieber[1,2,3], Hana Gmucová[3], Tereza Dekojová[1,2,3], Tomáš Kříž[1,2,3], Pavel Ostašov[1], Pavel Jindra[3], Daniel Lysák[3], Monika Holubová[1,2,3]

[1] Laboratory of Tumor Biology and Immunotherapy, Biomedical Center, Faculty of Medicine in Pilsen, Charles University

[2] Consortium of iNKT Research and Therapy (CiRT)

[3] Department of Hematology and Oncology, University Hospital Pilsen

HARNESSING THE CD1D-INKT CELLS AXIS WITH AN IMMUNE MODULATING SOLUBLE T CELL RECEPTOR (TCR) ENGAGER

Huw Ford, Richard Suckling, Daniel Fonseca and Mariolina Salio

ImmunocoreLTD, 92 Park Drive, Milton Park, Abingdon, OX14 4RY, UK

ALLOGENEIC CD33 CHIMERIC ANTIGEN RECEPTOR (CAR) –INVARIANT NATURAL KILLER T (INKT) CELLS AGAINST ACUTE MYELOID LEUKEMIA

Sisi Wang[1], Rebecca Richards[2], Hao Yan[3], Chaiyaporn Boonchalermvichian[3], Amandine Pradier[1], Astrid Melotti[1], Elena Sotillo[4], Robert Negrin[3], Federico Simonetta[1]

[1] Division of Hematology, Department of Oncology, Geneva University Hospitals and Translational Research Centre in Onco-Haematology, University of Geneva, Geneva, Switzerland

[2] Department of Pediatrics, University of Wisconsin-Madison, Madison, USA

[3] Division of Blood and Marrow Transplantation, Department of Medicine, Stanford University School of Medicine, Stanford, USA

[4] Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, USA

INVARIANT NATURAL KILLER T CELLS IN ACID SPHINGOMYELINASE DEFICIENCY PATIENTS

Fátima Macedo[1], Catarina Andrade[2], Inês Mondragão-Rodrigues[2], João Andrade[2], Teresa Cardoso[3], Arlindo Guimas[4], Paulo Chaves[3], Patrício Aguiar[5], Tiago Fonseca[2]

[1] Faculty of Medicine and Biomedical Sciences, University of Algarve, Faro, Portugal

[2] Institute for Research and Innovation in Health (i3S), University of Porto, Porto, Portugal

[3] São João University Hospital Center, Porto, Portugal

[4] Santo António University Hospital Center, Porto, Portugal

[5] Unidade Local de Saúde Santa Maria, Lisboa, Portugal

DEVELOPMENT OF AN EFFICIENT EXPANSION PROTOCOL FOR HUMAN CD4- INKT

Jordan Brouard[1], Cristina Caraiman[1], Tereza Coman[3], Marie-Thérèse Rubio[1,2]

[1] Lorraine University, CNRS UMR 7365 IMoPA, Vandoeuvre-lès-Nancy, France

[2] Hematology department, Nancy university hospital, Vandoeuvre-lès-Nancy, France

[3] Hematology department, Institut Gustave Roussy, Villejuif, France

ISOLATION AND EXPANSION OF INKT CELLS USING THE CLINIMACS PRODIGY PLATFORM

Andreas Nicodemou[1,2], Simona Jandová[1], Tomáš Zemánek[1,2], Daniel Lysák[3,4], Monika Holubová[3,4], Ivan Hutňan[1]

[1] GAMMA-ZA s.r.o., Trenčín, Slovakia

[2] Faculty of Medicine, Comenius University, Bratislava, Slovakia

[3] Department of Hematology and Oncology, University Hospital Pilsen, Pilsen, Czech Republic

[4] Laboratory of Tumor Biology and Immunotherapy, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic

FUNCTIONAL COMPARISON OF INVARIANT NATURAL KILLER T (INKT) CELL CULTURES THROUGH SINGLE CELL TRANSCRIPTOMICS

Joanna Dąbrowska[1], Pavel Ostašov[2], Monika Holubová[2], Aleksander Jankowski[1]

[1] Faculty of Mathematics, Informatics and Mechanics, University of Warsaw

[2] Biomedical Center, Faculty of Medicine in Pilsen, Charles University

DEVELOPMENT OF CAR-B7H3 REDIRECTED INKT CELLS FOR THE TREATMENT OF SOLID TUMORS

Whelan Eoin C[1], Sussman Jonathan[2,3,4], Swain John J[5], Srivastava Sonam[5], Fu Yao[6], Sun Yusha[7], Wang Xin[8], Foos Kay M[9,10], Pargiolas Isabella[10], Smith David[2], Cox Arin[5], Assenmacher Charles-Antoine[5], Radaelli Enrico[5], Nasrallah MacLean P[11], Binder Zev A[12], O' Rourke Donald M[12], Ming Guo-li[8], Song Hongjun[8], Mason Nicola J[5,10], Rotolo Antonia[5]

[1] Department of Biomedical Sciences, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA, USA.

[2] Children' s Hospital of Philadelphia, Philadelphia, PA, USA.

[3] Medical Scientist Training Program, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.

[4] Graduate Group in Genomics and Computational Biology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.

[5] Department of Pathobiology, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA, USA.

[6] Department of Biology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.

[7] Neuroscience Graduate Group, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.

[8] Department of Neuroscience and Mahoney Institute for Neurosciences, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.

[9] Department of Cancer Biology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.

[10] Center for Cellular Immunotherapy, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA.

[11] Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.

[12] Department of Neurosurgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.

THE TUMOR-ASSOCIATED MICROBIOME FUELS COLORECTAL CANCER THROUGH INKT CELL-DRIVEN IMMUNE EVASION MECHANISMS

Francesco Strati

Department of Biotechnology and Biosciences, University of Milano-Bicocca, Milan, Italy

BEHIND THE CURTAIN OF CLINICAL DATA SCIENCE

Kateřina Wolf[1,4], Jiří Fatka[1], Filip Jani[1,4], Tereza Dekojová[2,3,4], Monika Holubová[2,3,4], Lucie Houdová[1,4]

[1] Faculty of Applied Sciences, University of West Bohemia, Pilsen, Czech Republic

[2] Laboratory of Tumor Biology and Immunotherapy, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic

[3] Department of Hematology and Oncology, University Hospital Pilsen, Pilsen, Czech Republic

[4] Consortium for iNKT Research and Therapy (CiRT)

RECONSTITUTION OF INVARIANT NATURAL KILLER T CELLS POST-ALLOGENEIC STEM CELL TRANPLANT: PILOT DATA FOR PHASE I CLINICAL TRIAL

Tomáš Kříž[1,2,3], Hana Gmucová[1], Tereza Dekojová[1,2,3], Robin Klieber[1,2,3], Daniel Lysák[1], Pavel Jindra[1], Monika Holubová[1,2,3]

[1] Department of Hematology and Oncology, University Hospital Pilsen, Pilsen, Czech Republic

[2] Laboratory of Tumor Biology and Immunotherapy, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic

[3] Consortium for iNKT Research and Therapy (CiRT)